Abstract |
In their later stages low grade lymphoma are incurable. These lymphomas being radio-sensitive, a treatment of metabolic radioimmunotherapy, using monoclonal antibodies (anti-CD20) as the carrier has been developed. The aim of this treatment is to use these antibodies to target radiation to tumor tissues while limiting toxicity to normal cells. Ibritumomab tiuxetan ( Zevalin) is currently prescribed for patients with relapsed or refractory low-grade follicular lymphoma after rituximab treatment. This outpatient treatment has a high level of overall response rate including complete response and that for a long period. The side effects are essentially hematological and reversible. In the near future many more indications should become apparent and Zevalin should become an important tool in the B-cell lymphoma (low and high grade).
|
Authors | Nancy Witvrouw, Bernard De Prijck, Roland Hustinx |
Journal | Revue medicale suisse
(Rev Med Suisse)
Vol. 4
Issue 168
Pg. 1818-22
(Aug 27 2008)
ISSN: 1660-9379 [Print] Switzerland |
Vernacular Title | Indications cliniques de la radiothérapie métabolique dans les tymphomes. |
PMID | 18814766
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antibodies, Monoclonal
- ibritumomab tiuxetan
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Humans
- Lymphoma
(radiotherapy)
- Radioimmunotherapy
(methods)
|